Gevorg Tamamyan։ We Are Looking for Champions Around the World
Phase 3 BATTMAN Trial Launches BOT/BAL in MSS or pMMR Metastatic Colorectal Cancer
OncoDaily Grand Rounds at ASCO 2026: Sarcoma Edition
Waleed Arafat: Final Days to Submit Abstracts for ISCO 2026
Pavankumar Anné: Excited to be joining OncoDaily for the upcoming ZS AI in Oncology session during ASCO
2 New ES-SCLC Treatments Backed by EMA: A Major Shift in Care
Dr. Richard Goldberg on Why FDA Must Keep Pace as CRC Rises in Younger Adults
immunosarc II Trial: Sunitinib + Nivolumab in Advanced Clear Cell Sarcoma
Tracks percentage of skeletal tumor burden and change from baseline in metastatic bone disease. Designed for longitudinal monitoring and documentation of disease trend.
Trend thresholds: Stable within ±10% of baseline | Increase >10% | Decrease >10%
